skip to main content

Mucolytic therapy in COPD — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

EasyRespiratory TherapeuticsMucolytic therapy in COPDGPhC CRA

A 68-year-old man with COPD and an eGFR of 55 mL/min/1.73m² is prescribed a carbocisteine 375 mg capsule three times daily. He asks the pharmacist what the medication does. Which of the following best describes its mechanism?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — It is a mucolytic that reduces sputum viscosity to aid expectoration

Carbocisteine is a mucolytic agent that reduces sputum viscosity by altering the glycoprotein structure of mucus, making it easier to expectorate. It is recommended in COPD patients with a chronic productive cough where sputum management is problematic. It is not a bronchodilator, anti-inflammatory, antitussive, or antibiotic. NICE recommends considering a mucolytic in patients with a chronic productive cough and continuing if symptoms improve.

Reference: BNF Carbocisteine; NICE NG115 COPD